Alfimeprase

Summary

Alfimeprase (CHEMBL2108893) is a phase-3 clinical-stage enzyme; indicated across 3 conditions including thrombotic disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108893
Name	Alfimeprase
Type	Enzyme
Max phase	3

Also known as: Alfimeprasa, Alfimeprase, ALFIMEPRASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
thrombotic disease	3	MONDO:0000831	MONDO:0000831

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00115999	PHASE3	COMPLETED	Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
NCT00322270	PHASE3	COMPLETED	Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
NCT00338585	PHASE3	TERMINATED	Study of Alfimeprase’s Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
NCT00346424	PHASE3	COMPLETED	Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
NCT00073515	PHASE2	COMPLETED	Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
NCT00073554	PHASE2	COMPLETED	Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
NCT00499902	PHASE2	TERMINATED	Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).